Your browser doesn't support javascript.
Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients.
Butt, Batool; Hussain, Tajamul; Jarrar, Mu'taman; Khalid, Kashaf; Albaker, Waleed; Ambreen, Asma; Waheed, Yasir.
  • Butt B; Department of Medicine, Foundation University Islamabad, Islamabad 44000, Pakistan.
  • Hussain T; Research Chair for Biomedical Application of Nanomaterials, Biochemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
  • Jarrar M; Center of Excellence in Biotechnology Research, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
  • Khalid K; Vice Deanship for Quality and Development, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
  • Albaker W; Medical Education Department, King Fahd Hospital of the University, Al-Khobar 34445, Saudi Arabia.
  • Ambreen A; Multidisciplinary Laboratory, Foundation University Islamabad, Islamabad 44000, Pakistan.
  • Waheed Y; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
Antibiotics (Basel) ; 11(2)2022 Jan 25.
Article in English | MEDLINE | ID: covidwho-1649138
ABSTRACT
(1)

Background:

Immune compromised hemodialysis patients are more likely to develop COVID-19 infections, which increase the risk of mortality. The benefits of Remdesivir, despite less literature support on its effectiveness in dialysis patients due to renal toxicity, can outweigh the risks if prescribed early. The aim of this study was to evaluate the efficacy of Remdesivir on the 30-day in-hospital clinical outcome of hemodialysis population with COVID-19 infection and safety endpoints of adverse events. (2) Study

design:

A prospective quasi-experimental study design was used in the study. (3)

Methods:

The sample population consisted of 83 dialysis patients with COVID-19 who were administered Remdesivir at a dose of 100 mg before hemodialysis, as per hospital protocol. After the treatment with Remdesivir, we assessed the outcomes across two endpoints, namely primary (surviving vs. dying) as well as clinical and biochemical changes (ferritin, liver function test, C-reactive protein, oxygen requirements, and lactate dehydrogenase levels) and secondary (adverse effects, such as diarrhea, rise in ALT). In Kaplan-Meier analysis, the survival probabilities were compared between patients who received Remdesivir within 48 h of diagnosis and those who received it after 48 h. Cox regression analysis was employed to determine the predictors of outcome. (4)

Results:

Of the 83 patients, 91.5% survived and 8.4% died. Remdesivir administration did not reduce the death rate overall. Hospital stays were shorter (p = 0.03) and a nasopharyngeal swab for COVID-19 was negative earlier (p = 0.001) in survivors who had received Remdesivir within 48 h of diagnosis compared to those who had received Remdesivir after 48 h. The only variables linked to the 30-day mortality were serum CRP (p = 0.028) and TLC (p = 0.013). No major adverse consequences were observed with Remdesivir. (5)

Conclusions:

Remdesivir has the potential to shorten the recovery time for dialysis patients if taken within 48 h of onset of symptoms, without any adverse effects.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Antibiotics11020156

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Antibiotics11020156